NCT01938612 2021-03-12A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed269 enrolled
NCT02586987 2019-11-18A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed58 enrolled